Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

android tablet pc

Home > Press > Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy

* Study objective significantly exceeded
* Median survival time doubled
* Therapy shown to be highly effective, with minimal side effects
* Application for EU regulatory approval to be submitted before end of year

Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy

Frankfurt/ Berlin, Germany | Posted on November 3rd, 2009

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of phase II clinical trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

According to a previous study among a large patient population, the median survival time following diagnosis of a glioblastoma recurrence and treatment with conventional therapy (surgery, chemotherapy and radiation) is 6.2 months. The primary objective for the Nano-Cancer® therapy study was to demonstrate an extension of the median survival time in the recruited patient group by three months compared to this historical control group.

In fact, the median survival time of the 59 patients participating in the phase II clinical trials was 13.4 months following treatment with Nano-Cancer® therapy in conjunction with radiation. The median survival time was thus significantly greater, more than double that of the control population.

The results were even more remarkable in that Nano-Cancer® therapy was tested not on newly diagnosed patients with primary tumors but rather as a study involving patients who had already endured treatment with conventional therapies, as well as the unpleasant effects generally associated with these. Following regulatory approval of the new therapy, it is expected that it will also be available for use in treating other types of localized tumors, as these are generally responsive to the same principle of using warmth to destroy or degrade cancer cells.

MagForce founder and chief scientific officer Dr. Andreas Jordan commented, "The results demonstrate the potential of Nano-Cancer® therapy, which at the same time has minimal patient side effects. Our vision is to establish this new technology alongside surgery, chemotherapy and radiation as an additional pillar of cancer therapy."

Marco Beckmann, CEO of Nanostart AG, went on to add, "We enthusiastically congratulate Dr. Jordan and his team on the superb study results. It is my belief that we may thank nanotechnology for a historical advance in medical science."

In addition to its high efficacy of which has now been conclusively demonstrated, Nano-Cancer® therapy offers an additional and very significant advantage compared to the existing conventional therapy alternatives of surgical intervention, chemotherapy and radiation: Nano-Cancer® therapy is tolerated extremely well by patients and, despite its high efficacy, has no serious or unpleasant side effects.

The results of these clinical trials will now form the basis of application for EU regulatory approval for the new therapy, which will be submitted before the end of this year. Once EU regulatory approval has been obtained, MagForce will be able to market its Nano-Cancer® therapy throughout the European Union. The detailed study results will be published shortly in a medical journal.

Nano-Cancer® therapy represents a completely new way to fight cancer and is world's first approach to use magnetic nanoparticles to treat tumors with virtually no side effects. This is done by injecting specially coated iron oxide nanoparticles directly and precisely into the tumor so that they remain concentrated in the tumor and do not diffuse into the surrounding healthy tissue. The nanoparticles within the tumor are then heated to an exact temperature by externally applying an external magnetic field. In this way, tumor temperatures of up to 70°C (158°F) can be precisely attained within a fraction of a degree. This heat damages the tumor or destroys it completely. During the treatment procedure, patients feel only a moderate warming sensation.

Nanostart AG has been Lead Investor in MagForce Nanotechnologies since 2004 and currently holds approx. 77% of its shares.


About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit

About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors. For more information, please visit

Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

For more information, please click here

Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Canatu Launches CNB In-Mold Film for Transparent Touch on 3D Surfaces –in Cars, Household Appliances, Wearables, Portables November 20th, 2014

Sustainable Nanotechnologies Project November 20th, 2014

Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

UO-industry collaboration points to improved nanomaterials: University of Oregon microscope puts spotlight on the surface structure of quantum dots for designing new solar devices November 20th, 2014


Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014


Purdue 3-D printing innovation capable of making stronger, lighter metal works for auto, aerospace industries November 20th, 2014

Leica Microsystems Presents Universal Hybrid Detector for Single Molecule Detection and Imaging at SfN and ASCB: Leica HyD SMD - the Optimal Detector for Precise and Reliable SMD data November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Nano Sorbents Able to Remove Pollutions Caused by Oil Derivatives November 20th, 2014

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE